Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
주식 순위 #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
주가
$17.82
마지막 동기화: 2026-09-11
시가총액
$32.43B
변동 (1일)
0.83%
변동 (1년)
-25.31%
국가
JP
거래 Daiichi Sankyo Company, Limited (4568)

카테고리

Daiichi Sankyo Company, Limited (4568)의 수익
Jun 2026 기준 수익 TTM: $1.65B
Daiichi Sankyo Company, Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 $1.65B입니다. 2024년에 회사는 $1.57B의 수익을 올렸으며 이는 2023년의 수익 $955.41M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Daiichi Sankyo Company, Limited의 수익 기록 (2000 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $1.65B -30.33%
2025 $2.37B 51.37%
2024 $1.57B 64.05%
2023 $955.41M 58.24%
2022 $603.78M -9.78%
2021 $669.24M -49.03%
2020 $1.31B 69.80%
2019 $773.25M 1.40%
2018 $762.56M -3.25%
2017 $788.16M -27.54%
2016 $1.09B 63.21%
2015 $666.47M -31.10%
2014 $967.36M -1.02%
2013 $977.31M 139.07%
2012 $408.79M -71.86%
2011 $1.45B 39.41%
2010 $1.04B -133.26%
2009 $-3.13B -287.21%
2008 $1.67B 55.54%
2007 $1.08B -7.55%
2006 $1.16B 60.36%
2005 $725.65M -8.51%
2004 $793.11M 29.61%
2003 $611.93M 0.45%
2002 $609.17M -8.18%
2001 $663.43M -26.55%
2000 $903.21M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$33.59B 1,932.41%
US
$25.20B 1,424.32%
US
$8.70B 426.28%
US
$21.39B 1,193.96%
CH
$5.95B 259.84%
US